Abstract

Several drug candidates have been proposed and tested as the latest clinical treatment for coronavirus pneumonia (COVID-19). Chloroquine, hydroxychloroquine, ritonavir/lopinavir, and favipiravir are under trials for the treatment of this disease. The hyperpolarization technique has the ability to further provide a better understanding of the roles of these drugs at the molecular scale and in different applications in the field of nuclear magnetic resonance/magnetic resonance imaging. This technique may provide new opportunities in diagnosis and research of COVID-19. Signal amplification by reversible exchange-based hyperpolarization studies on large-sized drug candidates were carried out. We observed hyperpolarized proton signals from whole structures, due to the unprecedented long-distance polarization transfer by para-hydrogen. We also found that the optimal magnetic field for the maximum polarization transfer yield was dependent on the molecular structure. We can expect further research on the hyperpolarization of other important large molecules, isotope labeling, as well as polarization transfer on nuclei with a long spin relaxation time. A clinical perspective of these features on drug molecules can broaden the application of hyperpolarization techniques for therapeutic studies.

Details

Title
Signal amplification by reversible exchange for COVID-19 antiviral drug candidates
Author
Jeong, Hye Jin 1 ; Sein, Min 2 ; Chae Heelim 2 ; Kim, Sarah 2 ; Lee, Gunwoo 1 ; Namgoong Sung Keon 2 ; Jeong Keunhong 1 

 Korea Military Academy, Department of Chemistry, Seoul, South Korea (GRID:grid.453643.3) (ISNI:0000 0000 9061 1972) 
 Seoul Women’s University, Department of Chemistry, Seoul, South Korea (GRID:grid.412487.c) (ISNI:0000 0004 0533 3082) 
Publication year
2020
Publication date
2020
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
1893963100
Copyright
© The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.